Trutino Biosciences Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Trutino Biosciences's estimated annual revenue is currently $3.3M per year.(i)
  • Trutino Biosciences's estimated revenue per employee is $155,000

Employee Data

  • Trutino Biosciences has 21 Employees.(i)
  • Trutino Biosciences grew their employee count by 17% last year.

Trutino Biosciences's People

NameTitleEmail/Phone
1
CEOReveal Email/Phone
2
VP Research & DevelopmentReveal Email/Phone
3
Head Clinical developmentReveal Email/Phone
4
Director, Project ManagementReveal Email/Phone
5
Associate DirectorReveal Email/Phone
6
Senior Director, Antibody Engineering, Molecular and Protein SciencesReveal Email/Phone
7
Research AssociateReveal Email/Phone
8
Scientist, ImmunologyReveal Email/Phone
9
Senior ScientistReveal Email/Phone
10
Scientist, Protein Engineering and Antibody DiscoveryReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.4M70-8%$53MN/A
#2
$32.4M167-26%$110MN/A
#3
$0.9M60%N/AN/A
#4
$2.8M1813%N/AN/A
#5
$0.8M5-50%N/AN/A
#6
$0.8M100%N/AN/A
#7
$14M90-12%N/AN/A
#8
$0.4M33610%$236.7MN/A
#9
$4.8M62-74%$160MN/A
#10
$3.7M24-8%N/AN/A
Add Company

What Is Trutino Biosciences?

Trutino means ‘Balance’ in Latin, and this represents our strategy, namely an Rx/Dx approach for Precision Oncology Drug & Clinical Development. The company logo symbolizes well balanced wings. As it takes both wings to fly, we believe a balanced Rx/Dx drug development will ultimately deliver on the promise of Precision Oncology. Our effort focuses on ‘targeted destruction of cancer cells’ and simultaneous ‘differential activation of tumor-specific immune cells’ to maximize treatment response.

keywords:N/A

N/A

Total Funding

21

Number of Employees

$3.3M

Revenue (est)

17%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$4.3M215%N/A
#2
$1.5M21-5%$12M
#3
$1.5M21-16%$37M
#4
$2.1M21N/AN/A
#5
$2.1M21N/AN/A